When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
TEVA - Amgen Is On The Right Track With Its Own Biosimilar To Rituxan
Teva Pharmaceutical Industries Limited American Depositary Shares
Amgen (AMGN) and its partner Allergan (AGN) were able to achieve positive results in a comparative clinical study between their candidates ABP-798 and Rituxan. These positive results set up the biosimilar to potentially compete against Rituxan. This newly reported study focused on patients with CD20-positive B-cell non-Hodgkin's lymphoma ((NHL)). This reported data builds on prior data from another study, where the biosimilar drug was shown to be comparable to Rituxan in treating rheumatoid arthritis as well. Based on these results, things are moving along well for Amgen's biosimilar.